0849 GMT - Novartis is developing an experimental therapy that could raise the bar for the treatment of prostate cancer, Vontobel's Stefan Schneider says in a research note. The Swiss drugmaker released data from an early-stage clinical trial for its 225Ac-PSMA-617 drug candidate that showed so-called alpha particle radioactive isotopes should work in fighting prostate cancer, the analyst says. The new therapy differs from Novartis's approved Pluvicto prostate-cancer treatment in the radioisotope it uses to kill cancer cells, Vontobel says. Pluvicto carries a beta particle that travels for a longer range but is less lethal, while the new therapy uses an alpha particle that is more lethal but travels shorter distances, the analyst says. Deploying both could raise the bar for the treatment of prostate cancer, he adds. Shares fall 1.9%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 01, 2026 04:49 ET (08:49 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.